Khani S, Hejazi SA, Yaghoubi M, et al. - This research was intended to evaluate the effectiveness of concurrent magnesium-sodium valproate therapy and compare it with either magnesium or sodium valproate alone in migraine prophylaxis. Researchers performed a randomized single-center double-blind parallel-group controlled clinical trial study on migraine patients within the age range of 18–65 years. They randomized individuals with at least four monthly attacks to group A (n = 82) sodium valproate, group B (n = 70) magnesium with sodium valproate, and group C (n = 70) magnesium. This study’s findings demonstrate that magnesium could enhance the antimigraine properties of sodium valproate in combination therapy and decrease the required valproate dose for migraine prophylaxis. Intragroup data analysis indicated that headache frequency did not differ significantly between groups A and B in the third month; nevertheless, three other parameters were significantly lower in group B vs group A in the third month. On the other hand, group C could not effectively lower measured parameters in the patients vs groups A and B after 3 months.